TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26517595

Group type: EXPERIMENTAL
Intervention: SDM training for physicians (12 hours of training including decision aids)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: SDM training for physicians
Number of subjects: 160
Study: 23936756

Group type: EXPERIMENTAL
Intervention: Exercise training (n = 546)
Number of subjects: 2331

Group type: COMPARATOR
Intervention: Usual care (n = 507)
Number of subjects: 2331

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 2331

Group type: EXPERIMENTAL
Intervention: ICD presence
Number of subjects: 2331
Study: 21134505

Group type: EXPERIMENTAL
Intervention: Letrozole 7.5 mg daily for 2 days followed by 800 mcg vaginal misoprostol
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Letrozole 7.5 mg combined with 200 mg mifepristone
Number of subjects: 40
Study: 18284434

Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg daily
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Vildagliptin 100 mg daily
Number of subjects: 515

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 515
Study: 16502177

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 116

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 116
Study: 12772141

Group type: EXPERIMENTAL
Intervention: Posterior perineal block (PPB) with 0.75% ropivacaine, 40 mL
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (without PPB)
Number of subjects: 0
Study: 11253444

Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT) during hospitalization
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: NRT use among patients doing anything to help quit smoking at admission
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: NRT use among patients seriously planning to quit smoking within 30 days
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: NRT use among nicotine dependent patients
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: NRT use among patients offered prescription by a physician
Number of subjects: 580
Study: 9314128

Group type: EXPERIMENTAL
Intervention: Naltrexone (100 mg orally)
Number of subjects: 18
Study: 8380606

Group type: EXPERIMENTAL
Intervention: hBNP (2.0 pmol/kg.min)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 3490559

Group type: EXPERIMENTAL
Intervention: Thyroxine therapy
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation during thyroxine therapy
Number of subjects: 25

Group type: COMPARATOR
Intervention: Before treatment
Number of subjects: 25
Study: 29729429

Group type: EXPERIMENTAL
Intervention: Clindamycin administered intravenously 30 minutes before incision and every 8 hours for 24 hours post-operation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sterile saline administered
Number of subjects: 30
Study: 27484001

Group type: EXPERIMENTAL
Intervention: Progressive resistance training prior to the step-reduction intervention (PT-group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Home-based 'exercise snacking' three times per day during the step-reduction intervention (ES-group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Step-reduction intervention only (Control group)
Number of subjects: 30
Study: 25394805

Group type: EXPERIMENTAL
Intervention: 12-week recurrent fall prevention program (strength training, balance training, patient education)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 62
Study: 22345677

Group type: EXPERIMENTAL
Intervention: Tai Chi training
Number of subjects: 31

Group type: COMPARATOR
Intervention: Education programme
Number of subjects: 31
Study: 20202516

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (40 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg orally twice daily for 5 days) followed by Rosuvastatin (40 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Celecoxib (200 mg orally twice daily for 5 days) followed by Placebo
Number of subjects: 20
Study: 18209256

Group type: EXPERIMENTAL
Intervention: Move and learn curriculum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual curriculum
Number of subjects: 0
Study: 16314196

Group type: EXPERIMENTAL
Intervention: TMZ SPECT
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: LDDE
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo SPECT
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Revascularization
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Medical treatment
Number of subjects: 31

Group type: COMPARATOR
Intervention: No viability
Number of subjects: 31
Study: 12846468

Group type: EXPERIMENTAL
Intervention: Asset-tracking system using combined radiofrequency and infrared signals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no asset-tracking system)
Number of subjects: 0
Study: 11212905

Group type: EXPERIMENTAL
Intervention: DTIC 750 mg/m2 IV day 1 every 28 days (Arm A)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: DTIC 200 mg/m2 IV days 1-5 every 28 days (Arm B)
Number of subjects: 39
Study: 9344624

Group type: EXPERIMENTAL
Intervention: 50 ppm 13C2-BE vapor for 2 hours
Number of subjects: 6

Group type: COMPARATOR
Intervention: Blood sampling techniques (finger prick vs catheter)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Urine collection for 24 hours
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: PBPK modeling of worst-case exposure scenarios
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Simulated exercise with whole-body exposures
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Realistic exposures of only the arms and head
Number of subjects: 6
Study: 8472719

Group type: EXPERIMENTAL
Intervention: nisoldipine 10 mg twice daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: nifedipine 20 mg twice daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: atenolol monotherapy
Number of subjects: 24
Study: 2986275

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 68

Group type: COMPARATOR
Intervention: Alginate/antacid
Number of subjects: 68
Study: 31577035

Group type: EXPERIMENTAL
Intervention: Selepressin (1.7, 2.5, and 3.5 ng/kg/min; n=585)
Number of subjects: 868

Group type: COMPARATOR
Intervention: Placebo (n=283)
Number of subjects: 868

Group type: EXPERIMENTAL
Intervention: Selepressin (1.7, 2.5, and 3.5 ng/kg/min)
Number of subjects: 868

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 868
Study: 28412178

Group type: EXPERIMENTAL
Intervention: Universal screening and decolonization for MRSA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard precautions
Number of subjects: 0
Study: 25547064

Group type: EXPERIMENTAL
Intervention: High-dose vancomycin
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional-dose vancomycin
Number of subjects: 44
Study: 23953789

Group type: EXPERIMENTAL
Intervention: Propofol (n = 45 patients)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (n = 46 patients)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Volume expansion in PROP group
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Volume expansion in DEX group
Number of subjects: 91
Study: 22093213

Group type: EXPERIMENTAL
Intervention: Iron reduction (phlebotomy)
Number of subjects: 1277

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1277
Study: 19501292

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 33
Study: 17209786

Group type: EXPERIMENTAL
Intervention: Periodontal intervention (scaling and root planing, sonic toothbrush)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Periodontal intervention
Number of subjects: 67

Group type: COMPARATOR
Intervention: Pregnancy without periodontal treatment
Number of subjects: 67
Study: 12631411

Group type: EXPERIMENTAL
Intervention: beta‐cyclodextrin‐artemisinin complex (150 mg artemisinin)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Artemisinin 250 (250 mg artemisinin)
Number of subjects: 100
Study: 10869918

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside infusion at a rate of 1 to 2.5 mcg/kg/min to maintain moderate controlled hypotension
Number of subjects: 32

Group type: COMPARATOR
Intervention: Intravenous anesthesia supplemented with nitrous oxide (N2O)
Number of subjects: 32
Study: 9375480

Group type: EXPERIMENTAL
Intervention: Sickle cell disease patients
Number of subjects: 56

Group type: COMPARATOR
Intervention: Normal healthy controls
Number of subjects: 56
Study: 1589726

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 61

Group type: COMPARATOR
Intervention: No treatment with antibiotics (Control)
Number of subjects: 61
Study: 3840029

Group type: EXPERIMENTAL
Intervention: 1 g sucralfate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30226889

Group type: EXPERIMENTAL
Intervention: Subjects with metabolic risk factors
Number of subjects: 215

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 215
Study: 26969955

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection
Number of subjects: 60

Group type: COMPARATOR
Intervention: Arthroscopic double-row repair alone
Number of subjects: 60
Study: 23161345

Group type: EXPERIMENTAL
Intervention: SRP followed by diode laser (test)
Number of subjects: 30

Group type: COMPARATOR
Intervention: SRP alone (control)
Number of subjects: 30
Study: 22985137

Group type: EXPERIMENTAL
Intervention: Telephone administration
Number of subjects: 110
Study: 20594781

Group type: EXPERIMENTAL
Intervention: Aged garlic extract (960 mg containing 2.4 mg S-allylcysteine) daily for 12 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Aged garlic extract
Number of subjects: 50
Study: 17414091

Group type: EXPERIMENTAL
Intervention: Myocardial infarction by postoperative day 4
Number of subjects: 2102
Study: 16317370

Group type: EXPERIMENTAL
Intervention: Two drops of 0.5% tropicamide
Number of subjects: 12

Group type: COMPARATOR
Intervention: Single drop of unpreserved saline (Control)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Single drop of 0.5% tropicamide
Number of subjects: 12
Study: 11955905

Group type: EXPERIMENTAL
Intervention: Storz Hydroview H60M
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Corneal ACR6D
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Ioltech Stabibag
Number of subjects: 73

Group type: COMPARATOR
Intervention: Stabibag
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Hydroview and ACR6D
Number of subjects: 73
Study: 9708721

Group type: EXPERIMENTAL
Intervention: Amoxicillin and clavulanate every 12 hours (875 mg amoxicillin; 125 mg clavulanate)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Amoxicillin and clavulanate every 8 hours (500 mg amoxicillin; 125 mg clavulanate)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 170
Study: 9566550

Group type: EXPERIMENTAL
Intervention: VaxSyn (recombinant HIV envelope subunit vaccine)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Placebo (alum alone)
Number of subjects: 278
Study: 1897329

Group type: EXPERIMENTAL
Intervention: 200 IU of salmon calcitonin daily as a nasal spray
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo as a nasal spray
Number of subjects: 20
Study: 7043013

Group type: EXPERIMENTAL
Intervention: 0.5% malathion lotion (Prioderm lotion)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Alcoholic vehicle of the lotion
Number of subjects: 115
Study: 30541843

Group type: EXPERIMENTAL
Intervention: TbCSB iteron mutants
Number of subjects: 0

Group type: COMPARATOR
Intervention: TbCSV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SELEX assay
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Various betasatellite sequences
Number of subjects: 0
Study: 29061871

Group type: EXPERIMENTAL
Intervention: Drinking 500 mL of water before vaccination
Number of subjects: 1807

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 1807
Study: 23697602

Group type: EXPERIMENTAL
Intervention: Lapatinib (1000 mg/day) plus paclitaxel (80 mg/m2 per week, 3 of every 4 weeks) plus trastuzumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lapatinib (1000 mg/day) plus paclitaxel (70 mg/m2 per week, 3 of every 4 weeks) plus trastuzumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lapatinib (750 mg/day) plus paclitaxel (80 mg/m2 per week, 3 of every 4 weeks) plus trastuzumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All cohorts (combined)
Number of subjects: 0
Study: 21294998

Group type: EXPERIMENTAL
Intervention: mirtazapine
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: venlafaxine
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 65
Study: 19699781

Group type: EXPERIMENTAL
Intervention: Nav1.7 expression in patients with TN
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nav1.3 expression in patients with TN
Number of subjects: 0
Study: 17353512

Group type: EXPERIMENTAL
Intervention: Phenylephrine infusion to elevate nocturnal blood pressure to mean daytime values
Number of subjects: 12

Group type: COMPARATOR
Intervention: Isotonic saline (control condition)
Number of subjects: 12
Study: 15333483

Group type: EXPERIMENTAL
Intervention: Diazoxide (5-7.5 mg/kg in divided doses)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Diazoxide
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 11530277

Group type: EXPERIMENTAL
Intervention: Haloperidol (2 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9001476

Group type: EXPERIMENTAL
Intervention: Ad lib, low fat, high carbohydrate diet
Number of subjects: 43

Group type: COMPARATOR
Intervention: Fixed energy intake diet
Number of subjects: 43
Study: 8269785

Group type: EXPERIMENTAL
Intervention: Conventional therapy combined with daily oral aspirin 100mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 60
Study: 3666663

Group type: EXPERIMENTAL
Intervention: 120 mg diltiazem tablet (one tablet bid for 7 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 60 mg diltiazem tablet (two tablets bid for 7 days)
Number of subjects: 12
Study: 31211930

Group type: EXPERIMENTAL
Intervention: Defibrillation threshold testing (DT+)
Number of subjects: 501

Group type: COMPARATOR
Intervention: No defibrillation threshold testing (DT−)
Number of subjects: 501
Study: 29101186

Group type: EXPERIMENTAL
Intervention: Intensive treatment (target <120 mm Hg) with mean arterial pressure reduction <20 mm Hg
Number of subjects: 3090

Group type: EXPERIMENTAL
Intervention: Intensive treatment (target <120 mm Hg) with mean arterial pressure reduction between 20 and <40 mm Hg
Number of subjects: 3090

Group type: EXPERIMENTAL
Intervention: Intensive treatment (target <120 mm Hg) with mean arterial pressure reduction ≥40 mm Hg
Number of subjects: 3090

Group type: COMPARATOR
Intervention: Standard treatment (target <140 mm Hg)
Number of subjects: 3090
Study: 27631958

Group type: EXPERIMENTAL
Intervention: Face-to-face ECLA
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Telephone ECLA
Number of subjects: 257

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 257
Study: 24720376

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1200 mg bid for 8 weeks
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 22848894

Group type: EXPERIMENTAL
Intervention: Immediately loaded implant-supported prosthesis (test group)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Conventional denture (control group)
Number of subjects: 79
Study: 20835552

Group type: EXPERIMENTAL
Intervention: Sevoflurane + 0.1 mg/kg vecuronium
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 40
Study: 18192875

Group type: EXPERIMENTAL
Intervention: Somatostatin or its analogues
Number of subjects: 8
Study: 15977096

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2 % (Group R)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2 % plus 1 mg/kg tramadol HCl (Group RT)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2 % plus 0.1 mg/kg morphine HCl (Group RM)
Number of subjects: 53
Study: 14657745

Group type: EXPERIMENTAL
Intervention: Posterior lumbar interbody fusion (PLIF)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Anterior lumbar interbody fusion (ALIF)
Number of subjects: 119
Study: 10480700

Group type: EXPERIMENTAL
Intervention: Trisomy 18 cases (T18)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Maternal age >35 years (T18 cases)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Maternal age >30 years (T18 cases)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group (normal healthy newborns)
Number of subjects: 118
Study: 8944560

Group type: EXPERIMENTAL
Intervention: Cholera toxin (15 micrograms)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (no cholera toxin)
Number of subjects: 7
Study: 2066075

Group type: EXPERIMENTAL
Intervention: Aztreonam (0.5 gm every 8 hr for 14 days)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Cefotaxime (1 gm every 6 hr for 14 days)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Aztreonam
Number of subjects: 44

Group type: COMPARATOR
Intervention: Cefotaxime
Number of subjects: 44
Study: 6230897

Group type: EXPERIMENTAL
Intervention: Zimeldine
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study: 31093952

Group type: EXPERIMENTAL
Intervention: TNHH 0.2–1.8 mg/kg
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 30033422

Group type: EXPERIMENTAL
Intervention: Targeted nursing interventions combined with ear acupoint bean pressing treatment
Number of subjects: 158

Group type: COMPARATOR
Intervention: Hepatology nursing, liver protecting and transaminase lowering medicine, and ear acupoint bean pressing treatment
Number of subjects: 158
Study: 26399225

Group type: EXPERIMENTAL
Intervention: Tailored behavioural medicine treatment (EXT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Exercise-based treatment (CT)
Number of subjects: 32
Study: 25449153

Group type: EXPERIMENTAL
Intervention: Plant-derived anti-nociceptive spray
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 22157987

Group type: EXPERIMENTAL
Intervention: Intravenous zoledronic acid
Number of subjects: 181

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study: 19283736

Group type: EXPERIMENTAL
Intervention: Entonox (50% nitrous oxide and 50% oxygen)
Number of subjects: 131

Group type: COMPARATOR
Intervention: midazolam-fentanyl
Number of subjects: 131
Study: 17213237

Group type: EXPERIMENTAL
Intervention: 20 min locomotor training and 25 min physiotherapy (Group A)
Number of subjects: 155

Group type: COMPARATOR
Intervention: 45 min physiotherapy every weekday for four weeks (Group B)
Number of subjects: 155
Study: 16408140

Group type: COMPARATOR
Intervention: Famciclovir 1,000 mg b.i.d. for genital herpes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Famciclovir 1,500 mg single dose for labial herpes
Number of subjects: 0
Study: 11821099

Group type: EXPERIMENTAL
Intervention: Mifepristone (200 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 9658616

Group type: EXPERIMENTAL
Intervention: GenHevac B vaccine (3 standard injections at one month interval)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Alpha-Interferon (5 MU thrice weekly subcutaneously for 4 months)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Alpha-Interferon and Vidarabine (12 of 22 patients)
Number of subjects: 46

Group type: COMPARATOR
Intervention: preS2/S vaccine
Number of subjects: 46

Group type: COMPARATOR
Intervention: S vaccine
Number of subjects: 46

Group type: COMPARATOR
Intervention: No vaccine
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Vaccine therapy
Number of subjects: 46
Study: 8589319

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) at a dose of 0.125 IU/kg per week for the first 4 weeks and 0.25 IU/kg per week thereafter
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) therapy
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 12
Study: 2549780

Group type: EXPERIMENTAL
Intervention: Soy-polysaccharide fiber (SPF)
Number of subjects: 9

Group type: COMPARATOR
Intervention: No soy-polysaccharide fiber (without SPF)
Number of subjects: 9
Study: 185504

Group type: EXPERIMENTAL
Intervention: Etiroxate (40 mg daily) for 12 weeks
Number of subjects: 183

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 183
Study: 31274072

Group type: EXPERIMENTAL
Intervention: Simulator group
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 25
Study: 31321887

Group type: EXPERIMENTAL
Intervention: Immediate assisted partner services (aPS)
Number of subjects: 1119

Group type: COMPARATOR
Intervention: Delayed assisted partner services (aPS)
Number of subjects: 1119
Study: 27126371

Group type: EXPERIMENTAL
Intervention: Reactive soft tissue was debrided before implant placement (Group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Reactive soft tissue was left in the apical lesion (Group B)
Number of subjects: 60
Study: 26117072

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine (266 mg mixed with 75 mg 0.25% bupivacaine)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Bupivacaine (150 mg 0.25%)
Number of subjects: 111
Study: 23944203

Group type: EXPERIMENTAL
Intervention: Continuous infusion of beta-lactam antibiotics
Number of subjects: 420

Group type: COMPARATOR
Intervention: Intermittent bolus administration of beta-lactam antibiotics
Number of subjects: 420
Study: 21736815

Group type: EXPERIMENTAL
Intervention: High-viscosity viscous fibre blend (VFB)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Medium-viscosity psyllium (PSY)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Low-viscosity wheat bran (WB)
Number of subjects: 23
Study: 19579737

Group type: EXPERIMENTAL
Intervention: Immediate umbilical cord clamping (Group A)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Delayed umbilical cord clamping (Group B)
Number of subjects: 200
Study: 17166396

Group type: EXPERIMENTAL
Intervention: Resistance training and usual diabetes care (EX)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual diabetes care only (CON)
Number of subjects: 30